Recent Updates
Recently added Catalysts

SGR-1505

Phase 1

Mature B-Cell Neoplasm | Small molecule | Oncology |Schrodinger, Inc.|Trials Updated: Feb 13, 2026

SGR-1505 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2022

SGR-1505 target and mechanism

Molecular targetMALT1
Target classInhibitor
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment98

FDA Designations

No designations recorded

SGR-1505 clinical trials

SGR-1505 · 1 trial · 26 indications

Phase 1 1
NCT05544019Study of SGR-1505 in Mature B-Cell NeoplasmsMature B-Cell Neoplasm
RECRUITING98 Analytics
PHASE1RECRUITING
Study of SGR-1505 in Mature B-Cell Neoplasms
Mature B-Cell Neoplasm
NCT0554401998
Unlock trial analytics

Study Endpoints

Primary Endpoints

Nature, severity, and number of incidences of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation.
Throughout the study, up to 2 years.
Nature and number of incidences of dose limiting toxicity (DLT).
The first 21 days.

A DLT is an AE that requires treatment interruption.

Secondary Endpoints

SGR-1505 Maximal Plasma Concentration (Cmax)
Through study completion, up to 2 years.
SGR-1505 Time to Maximal Plasma Concentration (tmax)
Through study completion, up to 2 years.
SGR-1505 Area Under the Concentration Versus Time Curve (AUC)
Through study completion, up to 2 years.
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose EscalationEXPERIMENTALUp to 9 dose levels in total will be evaluated across two dosing schedules. Eligible patients will be assigned to a dose level cohort according to an accelerated titration design that will transition to a traditional 3+3 dose escalation.

Interventions

NameTypeDescription
SGR-1505DRUGSGR-1505 will be administered orally.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites36

Inclusion Criteria: * Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy. * Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment. * Eastern C...

Countries:United StatesFranceItalyMoldovaPolandRomaniaSpainUkraine
Unlock Eligibility Criteria

Other drugs targeting MALT1

AUR112 RDY· PHASE1 EXS73565 RXRX· PHASE1

Explore more on BiopharmaWatch

Schrodinger, Inc. (SDGR)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track